PL
AXSM icon

Parkwood LLC’s Axsome Therapeutics AXSM Stock Holding History

Parkwood LLC’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-7,532
Closed -$614K – 112
2020
Q4 		$614K Sell
7,532
-2,182
-22% -$163K 0.07% 101
2020
Q3 		$1.1M Sell
9,714
-2,746
-22% -$214K 0.17% 79
2020
Q2 		$1.02M Buy
+12,460
New +$959K 0.18% 74

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Parkwood LLC's AXSM Position: Q1 2021 in Review

Parkwood LLC sold out of Axsome Therapeutics (AXSM) in Q1 2021, closing a stake of 7,532 shares — an estimated $614K sold.

Parkwood LLC first reported a position in AXSM in Q2 2020 and held it in 3 quarters. The position peaked at $1.1M in Q3 2020. 184 funds tracked by Wall St. Rank hold AXSM as of Q1 2021.

  • Parkwood LLC reported no remaining Axsome Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Parkwood LLC sold 7,532 Axsome Therapeutics shares in Q1 2021, an estimated $614K.
  • Parkwood LLC first reported a position in Axsome Therapeutics in Q2 2020 and held it in 3 quarters.
  • Parkwood LLC's Axsome Therapeutics position peaked at $1.1M in Q3 2020.
  • 184 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2021.

Based on Parkwood LLC's 13F filing for Q1 2021, filed 14 May 2021.